Should immune checkpoint inhibitor be held for palliative RT to bladder in patient with metastatic urothelial carcinoma who has stable systemic disease on immunotherapy?  

What is the potential risk of immunotherapy toxicity in combining palliative RT in a patient already on immunotherapy?

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at University of Michigan Medical School
We have conducted and presented our study of nivo ...
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice